NImmune Biopharma unveiled promising early human trial results for NIM-1324, a Phase 2 drug candidate for Systemic Lupus Erythematosus, at the 2023 American College of Rheumatology Convergence.

Novo Nordisk presents cardiovascular results for Wegovy® (Semaglutide 2.4 mg) at the American Heart Association's scientific conference, also concurrently published in the New England Journal of Medicine.

Ionis Pharmaceuticals reported successful recruitment completion and encouraging early outcomes from the first phase of the HALOS Phase 1/2a trial for ION582 (BIIB121) targeting Angelman syndrome.

Initial Participant Receives Treatment in Phase III ProstACT GLOBAL Trial for Antibody-driven Prostate Cancer Candidate Therapy, TLX591.

Alnylam reports encouraging findings from the KARDIA-1 Phase 2 trial of Zilebesiran, a potential RNAi treatment, designed for addressing hypertension in individuals with significant cardiovascular risk.

Abelacimab 150 mg, a unique Factor XI/XIa inhibitor from Anthos Therapeutics, showcased a 67% decline in significant or notably relevant non-major bleeding versus Rivaroxaban in atrial fibrillation patients.

Novartis research suggests that remibrutinib, an oral medication, can effectively ease symptoms of chronic spontaneous urticaria as early as the second week of treatment.

Ocugen, Inc. declares commencement of Phase 1/2 trial after first administration on patient for OCU410ST - a modifier gene therapy for Stargardt Disease, assessing its safety and effectiveness.

Sana Biotech Reveals FDA Approval of New Drug Application for SC291, a Hypoimmune-modified, Targeting CD19, Allogeneic CAR T Treatment, Targeted for Lupus Nephritis, Extrarenal Lupus, and ANCA-linked Vasculitis Patients.

US FDA has given the green light to Takeda's ADZYNMA (recombinant-krhn, ADAMTS13) for the management of Congenital Thrombotic Thrombocytopenic Purpura (cTTP).

Boston Pharma shares promising Phase 2a results for potential once-a-month BOS-580 treatment in NASH and its impact on diabetic groups, showcased at the 2023 AASLD Liver Meeting.

Sirius Therapeutics reports its application to initiate the primary clinical testing of Factor XI siRNA, an advanced, long-lasting anticoagulant for blood clot issues.